Bimekizumab for the Treatment of Moderate to Severe Plaque Psoriasis with Scalp, Nail and Palmoplantar Involvement Through 52 Weeks: Post-Hoc Analysis from the BE VIVID Phase 3 Trial. J of Skin [Internet]. 2021 Jan. 1 [cited 2025 Apr. 19];5(1):s18. Available from: https://skin.dermsquared.com/skin/article/view/1171